GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Debt-to-Equity

Firebrick Pharma (ASX:FRE) Debt-to-Equity : 0.00 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Debt-to-Equity?

Firebrick Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.00 Mil. Firebrick Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.00 Mil. Firebrick Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$1.50 Mil. Firebrick Pharma's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Firebrick Pharma's Debt-to-Equity or its related term are showing as below:

ASX:FRE's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Firebrick Pharma Debt-to-Equity Historical Data

The historical data trend for Firebrick Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Debt-to-Equity Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Debt-to-Equity
- - - -

Firebrick Pharma Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Equity Get a 7-Day Free Trial - - - - -

Competitive Comparison of Firebrick Pharma's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firebrick Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Debt-to-Equity falls into.


;
;

Firebrick Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Firebrick Pharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 2.115
=0.00

Firebrick Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.497
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Firebrick Pharma  (ASX:FRE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Firebrick Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Debt-to-Equity
Comparable Companies
ASX:ECS ASX:CAN ASX:PER ASX:AGH ASX:NXS ASX:RGT ASX:EOF ASX:IVX ASX:EXL ASX:LGP LLY JNJ ABBV OCSE:NOVO B XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines